ASCO26 RASolute 302 (Daraxonrasib), PROTEUS (Apalutamide), & HARMONi-6 (Ivonescimab): The 3 trials we are tracking

Advertisement

Industry Spotlight

OncologyTube featured video thumbnail previewing practice-changing ASCO 2026 abstracts for RASolute 302, PROTEUS, and HARMONi-6 trials.

ASCO 2026 RASolute 302 (Daraxonrasib), PROTEUS (Apalutamide), & HARMONi-6 (Ivonescimab): The 3 trials we are tracking

May 19, 2026

The ASCO 2026 abstracts are released May 21st. While thousands of abstracts drop at ASCO, these three Plenary Phase III trials are the ones that might actually move the needle in your clinic. Top-line data already shows daraxonrasib (RASolute 302) nearly doubling median OS (13.2 vs 6.7 months, HR 0.40) in 2L+ metastatic pancreatic cancer. PROTEUS tests perioperative apalutamide to increase cure rates in high-risk localized prostate cancer. And HARMONi-6 pits the PD-1/VEGF bispecific ivonescimab against tislelizumab + chemo in 1L squamous NSCLC. Oncologists who watch this 5-minute breakdown will know exactly what to look for in the full data — key toxicities, subgroup results, and how these readouts could reshape standards of care in pancreatic, prostate, and lung cancer. Watch now to get the clear, high-yield context you need before the embargo lifts.

See Video & Read The Article...

Empowering Oncology Professionals with Knowledge, Insights, and Innovation.

Unsubscribe | Manage your subscription | View online